Osteopontin (OPN) is a secreted glycoprotein produced by osteoclasts, macrophages, T cells, hematopoietic cells, and vascular smooth muscle cells. It contributes to macrophage homing and cellular immunity. It also mediates neovascularization, inhibits apoptosis, and plays important roles in extracellular matrix remodeling and angiogenesis. These properties are also characteristics of metastatic cancer cells. Consequently, the OPN gene was found to be upregulated among various metastatic cancer cells. This suggests that OPN is involved in tumor metastasis. How the OPN gene is upregulated in metastatic cancer cells remains to be illustrated. Thus, we investigated the transcriptional activation of the OPN promoter in the human metastatic cancer cell line A2058. We cloned the OPN promoter, and serial deletion analysis of the OPN promoter showed that the region between -170 and -127 may act as an enhancer to control the OPN gene in metastatic tumor cells. This region was found to contain overlapped AML-1 and C/EBP binding site motifs. Gel-mobility-shift assays using the A2058 nuclear extract and AML-1a or C/EBPa (CCAAT/ enhancer binding protein alpha) recombinant protein indicated that these two transcription factors can bind to the overlapped AML-1 /C/EBP binding site motifs on the OPN regulatory sequence from -147 to -127. Surprisingly, the gel-shift experiments did not show supershift complex formation between AML-1 and C/EBPa. Functional analysis showed that the C/EBPa was more potent than the complex of AML-1 and its cofactor CBFb to upregulate the OPN promoter. In addition, AML-1 and C/EBPa did not exhibit transactivation additively or synergistically. Our results suggest that AML-1 and C/ EBPa play an important role in the upregulation of the OPN gene in metastatic tumor cells.
Introduction
Carcinogenesis is a process of multistep genetic changes resulting in a progressive transformation of normal human cells into highly malignant derivatives (Hanahan and Weinberg, 2000) . During the development of most types of human cancer, primary tumor masses produce unsteady cells that move out, invade adjacent tissues, and transfer to distant sites where they may succeed in forming new colonies. These distantly invasive tumor cells, metastases, are the cause of 90% of human cancer deaths (Sporn, 1996) , but their genetic and biochemical determinants remain incompletely understood. At the mechanistic level, for cancer cells to develop into metastatic cancer cells, at least four inter-related processes are involved: (a) activation of epithelialmesenchymal transition (EMT), (b) remodeling of the extracellular matrix (ECM), (c) migration to specific secondary sites, and (d) neoangiogenesis.
The ECM remodeling is one of the essential phenomena of tumor metastasis. It involves a set of enzymes. The involved enzymes not only digest the blood vessel walls and stroma at primary or secondary tumor sites but also increase the release of growth factors and cytokines by cleavaging membrane bound form (Lisa and Zena, 2002) . These released and activated growth factors and cytokines can in turn stimulate the proliferation of vascular endothelial cells and angiogenesis, and as a result, promote tumor cells proliferation. Several types of proteases are involved in these processes, such as cysteine/serine protease, heparanase, and matrix metalloproteinase (MMPs) (Baiker et al., 2000) . MMPs can promote cancer progression by destroying the basement membrane and other components of the ECM, increasing cancer cell growth, migration, invasion, metastasis, and angiogenesis (Mikala and Zena, 2002) .
In cultured transformed cells or metastatic cancer cells, there were abundant secretions of osteopontin (OPN) (Brown et al., 1994) . Previous studies have suggested that OPN is involved in ECM remodeling (Subha et al., 2001) , tumor invasion (Subha et al., 2001) , angiogenesis (Fumiyuki et al., 2002) , and regulating the production of urokinase (Mignatti and Rifkin, 1996) or MMPs (Anna et al., 1998) . These results indicated that OPN is an essential factor that participates in tumor metastasis.
OPN, a sialic acid-rich phosphorylated glycoprotein, is a cytokine produced by osteoclasts, macrophages, T cells, hematopoietic cells, and vascular smooth muscle cells (Weber, 2001) . It not only contributes to cellular immunity and macrophage homing, but also induces migration of immune cells and invasion to inflammatory sites in host-resistant systems (Nau et al., 1999; Chabas et al., 2001) . It is believed that tumor cells require the same mechanism in the process of metastasis.
Structurally, OPN has an RGD amino-acid sequence, which is able to bind cell-surface integrins (e.g. avb3) that are important in endothelial cell biology and neovascularization (Rittling et al., 2002) . OPN can also bind cell surface receptors (e.g. CD44), but it has been demonstrated that the binding of OPN to CD44 is independent of RGD (Weber et al., 1996) . CD44 is not only implicated as involved in cell adhesion, migration, and metastasis but also interacts with MMPs, which can degrade the extracellular matrix and induce cell invasion (Helmut et al., 2003) . Thus, the OPN-bound CD44 may be associated with signaling involved in tumor metastasis. OPN can also inhibit apoptosis and contribute to cell survival in toxicant injury systems (Weber, 2001) . The antiapoptosis effect depends on phosphorylation of OPN (Kaartinen et al., 1999) . The host-derived OPN may act as a macrophage chemoattractant (Kaartinen et al., 1999) , whereas the tumor-derived OPN can inhibit the function of macrophage and enhance the growth of metastasis (Crawford et al., 1998) .
Thus, the expression of OPN plays an important role in the tumor metastasis process. However, it is not clear as to what factors are involved in the regulation of OPN expression in metastatic cancer cells. We isolated the promoter of OPN and analysed the regulatory sequence for factors that interact with this sequence. Previous studies of the OPN promoter have been demonstrated on normal cells from the immune system (Nau et al., 1999; Chabas et al., 2001) . However, it is not clear whether the tumor cells use the same mechanism during metastasis. It is possible that certain types of transcription factors would be involved in up-or downregulation of the OPN gene. In this study, we investigated the transcriptional regulation of OPN expression in human melanoma tumor cells.
Results

Expression of the OPN gene in cancer cell lines
OPN is not detected in the cell matrix of most normal tissues except of mineralized tissues; however, it is abundantly secreted by various carcinoma cells and transformed cells. In order to investigate the regulation of OPN expression in cancer cells, RT-PCR was carried out to measure the levels of OPN in various cancer cell lines. The OPN transcript was detected in lung cancer cell line CLI-5 (Figure 1 . All these cells were highly metastatic, but OPN was not expressed in the others nonmetastatic cell lines. Subsequently, A2058 and CLI-5 cell lines were used for functional analysis of the OPN promoter in luciferase reporter assay by transfection of various promoter constructs into these cell lines.
Functional assay of the OPN promoter
Serially deleted OPN promoter constructs were inserted into luciferase promoter plasmid pGL3 and cotransfected with Renilla into A2058. When luciferase activities of transfected cells were analysed, the regions between À500 and À170 and between À127 and À97 showed basal level of activities (Figure 2 ). These regions may contain a repressor-binding sequence. However, two regions of positive regulation were identified. One was located between À97 and À79 and another was located between À170 and À127. The sequences between À170 and À127 showed more pronounced positive Figure 1 The OPN transcripts in various tumor cells. Equal amounts (2 mg) of total RNA from various cell lines were converted to ss-cDNAs by reverse transcriptase. Equal amounts of these cDNAs were used as a template for PCR using OPN primers that covered the entire coding sequences of OPN. The GAPDH primers served as control. The PCR product for OPN was 904 bps (a), whereas that for GAPDH was 350 bps (b) Various lengths of OPN promoters were generated by PCR and inserted into reporter vector pGL3. These constructs were cotransfected with an internal control vector (Renilla) into A2058 cells in duplicates or triplicates. The luciferase activities were analysed from the cell lysates extracted from cells 48 h after transfection. The luciferase activities were expressed as folds over that of the promoter-less reporter vector (pGL3) regulatory activity. The 22 bp between À97 and À79 has been shown to contain overlapping GRE and c-Myc (E-box) elements (Dongyan et al., 2000) . The 43 bp between À170 and À127 has not previously been reported to have a positive regulatory function on the OPN promoter (Weber, 2001 ). Thus, we analyse the functions of these sequences in more detail.
Database analysis of OPN regulatory sequence
Database analysis (www.cbrc.jp/htbin/nph-tfsearch) of the 43 bp between À170 and À127 for known consensus sequences indicated the presence of binding sites for AML-1 and C/EBP (Figure 3 ). These two binding sites were found to be overlapping in the OPN regulatory sequence. The AML-1 binding site was located between À138 and À132, whereas the binding site for C/EBP was located between À144 and À131.
Construction and purification of various expression constructs
Database searches for the transcription factors that probably can bind to the OPN regulatory sequence were AML-1 and C/EBP. Previous reports indicated that these transcription factors have different members. In order to understand the relation of these transcription factors and the OPN regulatory sequence, various types of AML-1 and C/EBP transcription factors cDNA were inserted into two different types of expression vectors (pcDNA3 and pGEX-KG) (Tables 1 and 2 ). Vector pcDNA3 was used for the cotransfection assay and vector pGEX-KG was used for the recombinant fusion protein purification for gel-shift analysis.
Interaction between A2058 nuclear extract and the OPN regulatory sequence and the AML-1 binding site
To assess the nuclear extract that interacted with these binding sites, a labeled 20 bp oligonucleotide probe covering OPN À147 to À127 was mixed with a nuclear extract prepared from the A2058 cell line. The products of interaction were analysed by electrophoresis mobility (Figure 4 , lanes 3 and 4). The oligonucleotides containing part of the probe sequences (À159 to À137) competed less well with the probe for the nuclear extract (Figure 4 , lanes 5 and 6). The homologous oligonucleotide mutant or oligonucleotides representing the nonoverlapped region (À170 to À147) could not compete with the probe for the complex formation with the A2058 nuclear extract (Figure 4 , lanes 7-10). These results suggest that certain proteins in A2058 nuclear extract may interact with the OPN regulator sequence between À147 and À127.
To characterize the interactions of C/EBP and AML-1 binding sites with the A2058 nuclear extract in more detail, the competition oligonucleotides representing canonical C/EBP and AML-1 binding sites were used to compete the interaction between the nuclear extract and the probe. In addition, labeled 12 mer oligonucleotides representing the AML-1 binding site in the OPN promoter were allowed to interact with the nuclear extract and EMSA was carried out. Competition effects were shown ( Figure 5 , lanes 3 and 4) and a major specific complex was detected ( Figure 5, lane 8) . Surprisingly, the unlabeled AML-1 binding site oligonucleotides ( Figure 5 , lanes 3 and 9-11) competed less well for the A2058 nuclear extract than the unlabeled C/EBP binding site oligonucleotides ( Figure 5 , lanes 4 and 15-17). These unlabeled competition oligonucleotides have specific binding ability for AML-1 and C/EBPa (CCAAT/ enhancer binding protein alpha) transcription factors. These results appear to suggest that most of the proteins expressed in A2058 cells might bind preferentially to the C/EBP binding site rather than the AML-1 binding site.
Interaction between recombinant AML-1, CBFb, and C/EBPa with OPN À147 to À127 oligonucleotides To characterize the AML-1 and C/EBP binding sites further, recombinant AML-1a, CBFb v1, and C/EBPa were purified and analysed by gel-shift assay. The Interaction between A2058 nuclear extract (NE) and OPN À147 to À127 oligonucleotides. A 1 ng measure of labeled OPN À147 to À127 oligonucleotides were mixed with 3 mg of A2058 NE. The reaction products were analysed by EMSA. The competing oligonucleotides represented homologous OPN À147 to À127 (lanes 3 and 4) and immediate upstream (lanes 5-8) and homologous mutants (lanes 9 and 10) of this site. C1: complex one recombinant GST/AML-1a fusion protein formed a complex with labeled oligonucleotides representing the overlapped AML-1/C/EBP binding sites ( Figure 6 , lane 2), whereas the GST/CBFb fusion protein did not ( Figure 6 , lane 3). However, CBFb could bind with AML-1a to let the complex migrate slower ( Figure 6 , lane 9). Competition unlabeled oligonucleotides homologous with the probe or AML-1 binding site showed the competition effect ( Figure 6 , lanes 5,7,10 and 13), whereas the mutant form of these oligonucleotides could not compete with the probe (Figure 6, lanes 6, 8, 11 and 12) . Similarly, the recombinant C/EBPabZIP (containing only the DNA-binding domain)/GST fusion protein also formed a complex with the labeled oligonucleotides of the OPN regulatory sequence between À147 and À127 ( Figure 7 , lane 2). Unlabeled specific or C/EBP binding site oligonucleotides also showed competition between nuclear extract and the probe ( Figure 7 , lanes 4-7), whereas the mutant form of these oligonucleotides could not ( Figure 7 , lanes 8 and 9). These results indicated that both the AML-1a/CBFb and C/EBPa transcription factors could interact with the OPN regulatory sequence from À147 to À127.
Interaction between A2058 nuclear extract and OPN À147 to À127 in the presence of anti-AML-1a and anti-C/EBPa
To ascertain that the complexes detected were due to the AML-1a or C/EBPa, antibodies against AML-1a or C/EBPa were used in gel-shift analysis. Anti-AML-1a (prepared against N terminus AML-1a) could supershift (the preparation of soluble recombinant C/EBPa protein was unsuccessful, therefore, it could not be tested in the gel-shift assay). These results suggest that the proteins binding to the overlapped AML-1/C/EBP binding site on the OPN regulatory sequence were AML-1a and C/EBPa. In addition, the gel-shift experiments did not show the supershift complex formed between the C/EBPabZIP/GST and AML-1Runt/GST recombinant protein ( Figure 9 ). This result indicated that C/EBPa and AML-1 transcription factors may bind to the overlapped AML-1/C/EBP binding site, but it depends on their spatial structure.
Transactivating activity of AML-1 family member transcription factors and CBFb on the OPN regulatory sequence
Since one of the positive regulatory elements in the OPN regulatory sequence contained an AML-1 binding site and the results of EMSA showed that the nuclear extract from metastatic melanoma cells formed a complex with these elements, AML-1 transcription factors and their cofactor CBFb were examined on the OPN regulatory sequence by cotransfection assay. Different members of the AML-1 family members were studied with respect to the activation of the OPN regulatory sequence. AML-1a could increase OPN promoter activity over 50% ( Figure  10a , lane 2), whereas AML-1b (Figure 10a , lanes 3-5) and AML-1c (Figure 10a , lane 7) could increase the OPN activity more than twofold. Surprisingly, AML-1b with the point mutation (L148D) that was supposed to abolish its DNA-binding ability could still activate the OPN regulatory sequence (Figure 10a , lane 6). To characterize the effect of AML-1b and its cofactor CBFb on the OPN regulatory sequence, AML-1b/CBFb and OPN-170/20 has been used for cotransfection assays. CBFb could not trans-activate the OPN promoter construct because it did not have DNAbinding ability (Figure 11a, lane 4) . With the addition of CBFb, the trans-activation effects of AML-1b were greatly enhanced on OPN promoter constructs ( Figure  10b , lane 6 and Figure 11a , lane 5). When the transactivation domain was removed (dominant-negative AML-1) to compete with the wild-type domain, the trans-activating ability from both the AML-1b and AML-1/CBFb heterodimers on the OPN-170/20 reporter constructs was abolished (Figure 10b , lanes 3-5 and 7-9). A two-sample t-test showed that the distinctions between lanes 2 and 3 and between lanes 6 and 7 in Figure 8 Interaction between the A2058 nuclear extract and OPN À147 to À127 in the presence of anti-AML-1a and anti-C/EBPa. A 1 ng measure of labeled OPN À147 to À127 oligonucleotides were mixed with 5 mg A2058 nuclear extract (lanes 5-11) or 3 mg of recombinant AML-1a GST fusion protein (lanes 13-15). The mixtures were kept on ice for 30 min, and then mixed with 3 mg/5 mg either anti-AML-1a (prepared against AML-1a N-20) (lanes 2,6,7, and 14), anti-C/EBPa (prepared against C/EBPa N-19) (lanes 3,8,9, and 15), or anti-C/EBPa (prepared against C/EBPa C-18) (lanes 4,10, and 11) at room temperature for 30 min. The reaction products were analysed as described in Materials and methods Transactivating activity of AML-1, CBFb, and C/EBPa on the OPN regulatory sequence
Besides the AML-1 binding site on the OPN promoter, additional investigation showed that the C/EBP binding site overlaps with that of AML-1. To compare the transactivation activities of AML-1 and C/EBPa on the OPN promoter, their transactivating activity was analysed by cotranfection analysis. C/EBPa is more potent in transactivating the OPN promoter than AML1b ( Figure 11b , lane 2 vs 4). AML-1b required its coactivator, CBFb, to reach a similar level of transactivation of the OPN promoter (Figure 11b, lane 5) . A two-sample t-test showed that the difference between lanes 2 and 4 and between lanes 4 and 5 in Figure 11b was significant (Po10 À6 ). In addition, the transactivation of AML-1b and C/EBPa was not shown additively or synergistically on the OPN regulatory sequence (Figure 11b, lanes 6 and 7) . Furthermore, the dominant-negative C/EBPa (containing only the basic regionleucine zipper domain as shown in Table 1 ) could efficiently reduce the transactivation activity of the wildtype C/EBPa (Figure 11c, lanes 3-5) . A two-sample t-test showed that the distinction between lanes 2 and 3 in Figure 11c was also significant (Po10
À6
). These results indicated that both AML-1 and C/EBPa could upregulate the expression of OPN. 
Discussion
Under normal physiological conditions, OPN plays an important role in the cells of the immune system, especially in macrophages (Nau et al., 1999; Chabas et al., 2001) . It is involved in cell migration (Nau et al., 1999) , remodeling of the extracellular matrix (Subha et al., 2001) , and angiogenesis (Fumiyuki et al., 2002) . These functions are also characteristics of cancer cell metastasis. In most of the metastatic cancer cells, an increase in OPN gene expression and the OPN secretion can be found. Thus, OPN has been suggested to be involved in the process of cancer metastasis (Weber, 2001) . Previous studies showed that a number of transcription factors have been found to recognize their binding sites in the regulatory region of the OPN gene, and showed the effects of transcription factors on the OPN gene expression using fibroblast and epithelial cells derived from various mammalian species (Sato et al., 1998; Shi et al., 2001) , or astrocytoma cell lines (Dongyan et al., 2000) . However, the mechanism of OPN upregulation in human metastatic cancer cells is not clear. Several studies have shown the correlation between OPN and the metastatic potential of cancer cells and suggested that the OPN may act as a useful marker for the metastatic progression of cancer cells (Rudland et al., 2002) . Thus, investigation of the expression of OPN in metastatic cancer cells would lead us to a better understanding of the process of cancer metastasis. When RT-PCR was used to examine the OPN gene expression in various cancer cells, the OPN messenger was readily detected in CLI-5, A2058, BT483, and HL60 cell lines. CLI-5, A2058, and BT483 cells have the ability for distant metastasis, whereas HL60 are hematopoietic cells. In contrast, most of the nonmetastatic cancer cells' OPN was not expressed. These results indicated that metastatic cells might synthesize more cytokine proteins (e.g. OPN) through its receptors or integrins to promote cell neovascularization (e.g. avb3) or other inter-related processes than nonmetastatic cells. A2058 is a human melanoma cancer cell line and it showed the most abundant OPN expression in our result; therefore, it was used throughout this study. Thus, using the metastatic melanoma cells to demonstrate the OPN gene transcriptional regulation may implicate this gene with respect to the mechanisms of cancer metastasis at the mRNA level.
In this study, serial deletions of the OPN regulatory sequence were attached to a luciferase reporter. These constructs were used for the functional analysis in the A2058 cell line. Our results showed two regions of possible repressor activities of the OPN promoter. These will be the focus of our future investigation. These results indicated that enhancer elements to activate OPN gene expression in metastatic cancer cells are present between À170 to À127 and À97 to À79 in the regulatory region of the OPN gene. The elements between À97 and À79 have been reported to contain E-box and can upregulate the OPN gene expression in human malignant astrocytoma cell lines (Dongyan et al., 2000) . The function of the region from À170 to À127 in the OPN gene is still not clear. Using the A2058 nuclear extract and OPN regulatory region between À147 and À127 as a probe for gel-shift assays, one complex was detected. These results indicate that certain types of proteins in the A2058 nuclear extract may interact with the OPN gene between À147 and À127. The database analysis suggested that the responsible transcription factors may be C/EBPa and AML-1. C/EBPa and AML-1 recombinant transcription factors were isolated by protein purification. The purified transcription factors were then used in gel-shift assay to determine their function in relation to the OPN gene from À147 to À127. The results showed that both recombinant C/EBPa and AML-1 transcription factors were capable of binding to the À147 to À127 regions. Therefore, the OPN promoter between À147 and À127 indeed contains the regulatory sequences that are binding sites for transcription factors C/EBPa and AML-1. Antibodies against AML-1a (prepared against AML-1a N-20) or C/EBPa (prepared against C/EBPa N-19/C-18) could supershift the complex formed between A2058 nuclear extracts and probes by gel-shift analysis. These results demonstrate that C/EBPa and AML-1 may express themselves in the A2058 cell line and can interact with the OPN gene between À147 and À127. Results from cotransfection analysis using vectors expressing AML-1 or C/EBPa and the OPN-reporter constructs that contain these transcription factor-binding motifs in A2058 cells showed that C/EBPa and AML-1 transcription factors indeed can upregulate the OPN genes in metastatic cancer cells. Thus, C/EBPa or AML-1 may act as positive transcription factors to cause upregulation of the OPN gene and may increase OPN secretion in metastatic cancer cells.
AML-1 (CBFa2), a core binding heterodimeric transcription factor, can cooperate with its cofactor CBFb (core binding factor b) to activate its target genes. The heterodimer of AML-1/CBFb recognizes the Pu/ TACCPuCA DNA-binding motif (Miyoshi et al., 1995) . AML-1 contains an evolutionarily conserved runt domain that has DNA binding and heterodimerization function (Meyers et al., 1993; Levanon et al., 1994) , whereas CBFb, a non-DNA binding factor heterodimerizes with a subunits and increases DNA-binding ability (Zhang et al., 1996) . The AML-1 and CBFb are frequently involved in chromosomal translocation (Meyers et al., 1995) , inversion (Liu et al., 1993) , and point mutations (Miyoshi et al., 1995) in various types of leukemia diseases. In addition, AML-1 plays important functions in early hematopoietic development, whereas the structurally abnormal AML-1 plays a direct role in the transformation of hematopoietic stem cells (Lorsbach and Downing, 2001 ). AML-1 has also been reported to upregulate myeloid cell growth and differentiation by controlling the osteoblast-restricted gene secretion (Lorsbach and Downing, 2001; Lund and Van, 2002) . Thus, AML-1/CBFb appeared to be involved in various types of transformed cells related to the cell growth and possibly cell migration. OPN is a phosphoprotein secreted from epithelial, mesenchymal, and hematopoietic cells (Gang et al., 2001) , and is involved in tissue remodeling and cell migration (Weber, 2001) . Thus, during cell transformations, AML-1 could be involved in controlling the OPN gene expression. CBFb expression is ubiquitous (Liu et al., 1993) , and acts as a cofactor to cooperate with AML-1 to control the target genes. This study has shown that OPN was overexpressed in various types of metastatic cancer cells. It is likely that AML-1/CBFb may be involved in the OPN expression during the process of cancer metastasis.
This report also showed that the transcription factor C/EBPa can transactivate the OPN promoter to a similar or lightly higher level as that of AML-1/CBFb heterodimer. C/EBPa is a typical basic region-leucine zipper (bZIP) transcription factor (Per and Kleanthis, 1995; Dipak and Pelagia, 2002) . There are five other members of this transcription factor family. All of them contain a conserved bZIP domain at the C-terminal. It is expressed at a high level not only in the placenta, lung, colon, and peripheral blood leukocytes (Per and Kleanthis, 1995; Dipak and Pelagia, 2002) but also more frequently in adenocarcinoma cells (Tomizawa et al., 2002) . Thus, C/EBPa may contribute to the development of malignancies in a variety of tissues. Since OPN has been showed to be involved in various types of cancer and related to the expression of hematopoietic cells, investigation of the regulation of the OPN gene by C/EBPa in cancer cells may help us to understand the mechanism underlying the tumorigenesis process better. In addition, C/EBPa can form a heterodimer with other transcription factors, including AML-1b, PU.1, and others to upregulate the expression of several myeloid cell-specific gene promoters synergistically (Zhang et al., 1996; Petrovick et al., 1998) . In this study, the C/EBP binding site overlaps the AML-1 binding site and occupies more base pairs than AML-1 in the promoter region of the OPN. A transfection assay showed that C/EBPa can transactivate the OPN gene better than the AML-1/CBFb heterodimer (P ¼ 0.05). Both could be expressed in different amounts depending on the different type of cells or the physiological conditions in participating transactivation of the OPN gene. Furthermore, the gelshift experiments did not show interaction between C/EBPa and AML-1. Therefore, the structure or distribution of transcription factor binding sites on the regulatory region of a gene would be an important factor that determines which transcription factor(s) will be favorable to activate its target gene.
The results of this study showed that in metastatic cancer cells, C/EBPa has more transactivation effect than members of the AML-1 family transcription factors and has the binding ability in the OPN regulatory sequence at À144 to À131, whereas the AML-1 binding site is included in the OPN regulatory sequence at À138 to À132. Furthermore, the upregulated expression of OPN may act to influence tumor cells migration or ECM remodeling. Thus, this evidence suggested that these transcription factors play an important role in the migration and angiogenesis of metastatic tumor cells to control their migratory properties. Their active role in transactivating the OPN gene in tumor cells may help these cells to show metastatic phenotypes.
Materials and methods
Cell lines and cell culture
The following cell lines were used in this study: lung carcinoma cell lines: CLI-0, CLI-3, and CLI-5; melanoma cell line: A2058; leukemia cell lines: K562 and HL60; colon cancer cell line: colo205; breast cancer cell lines: MCF7, T47D, MDA361, and BT483. Lung carcinoma and leukemia cell lines were grown in RPMI media supplemented with 10% fetal calf serum (FCS). The other cell lines were grown in DMEM supplemented with 10% FCS.
RNA isolation and RT-PCR
When cells reached 80% confluence, they were harvested and RNAs were extracted using the acid quanidinium method (Chirgwin et al., 1979) . RNA (2 mg) from each cell line was converted into single-stranded (ss-) cDNA primed by oligo dT using the SuperScript preamplification system for first-strand cDNA synthesis kit (GibcoBRL Life Technologies, Inc.) following the vender's protocol. A 1 ml measure of each sscDNA was used as a template to generate OPN cDNA. The sequence of the forward primer was: 5 0 -AAGCTTCCATGG-GAATTGGAGTGATTTGCTTTTGCCTC-3 0 and that for the reversed primer was: 5 0 -GGATCCTTAATTGACCTCA-GAAGATGCACTATCTAA-3 0 . The PCR program was: 951C, 5 min followed by 35 cycles of 951C, 1 min, 561C, 1 min, and 721C 1 min. At the end of the PCR, the reaction was extended for 8 min at 721C then cooled down to 41C. Aliquots of PCR products were analysed by electrophoresis in 1% agarose. The expected OPN products were 904 bps.
Isolation of OPN promoter and serial deletion constructs of the OPN promoter
The OPN promoter sequence from 500 bp upstream to 20 bp downstream of the OPN transcription start site was cloned by genomic PCR using human genomic DNA as a template. Various size deletions of the promoter were generated also by PCR with various 5 0 primers and a fixed 3 0 primer. The sequences of these forward primers were:
0 (À79/20). The reversed primer was: 5 0 -GAGCTCTGCCTCCTCCTGCTGCTGCTGACAACCAAG-3 0 . To facilitate the functional analysis of various OPN promoter constructs, the 5 0 end primers were attached with the KpnI, BamHI, or EcoRI site and the 3 0 end primer was attached with the SacI site (Figure 2 ). The PCR program was the same with OPN cDNA PCR. These OPN promoter fragments were cloned into promoter-less luciferase reporter plasmid pGL3 (Promega).
Expression vector constructs
The AML-1b and AML-1bM cDNAs were obtained from Drs Noel Lenny and Jim Downing, St Jude Children's Research Hospital, Memphis, TN, USA. AML-1a and AML-1c cDNAs were obtained from Dr H Miyoshi, National Cancer Research Institute, Tokyo, Japan. C/EBPa/pcDNA3 was obtained from Dr D Tenen, Harvard Medical School, Boston, MA, USA. CBFb cDNA was generated by RT-PCR using A2058 sscDNA. The cDNA encoding only the Runt domain of AML-1 and the basic region-leucine zipper domain of C/EBPa were also generated by PCR. All cDNAs were inserted into the eucaryotic expression vector pcDNA3 for cotransfection experiments as described in the text and are listed in Table 1 .
All cDNAs were also inserted into the procaryotic expression vector pGEX-KG (Guan and Dixon, 1991) . The recombinant constructs were transformed into Escherichia coli strain BL21 (Promega). To synthesize the recombinant proteins, the transformed bacteria were induced with 1 mm IPTG for 3-4 h at 271C. Bacteria were collected by centrifugation. The bacterial pellets were resuspended with PBST (PBS with 0.5% Triton 100, and 0.2 mm PMSF), crushed with French press. The supernatants were separated from bacterial debris and centrifuged at 13 K r.p.m. for 20 min in a Sorvall SS34 rotor. The supernatants containing bacterially synthesized fusion proteins were passed through columns of glutathione-sepharose beads, washed, and then eluted with 10 mm glutathione. The fractions containing fusion proteins were dialysed against the EMSA buffer (see below) overnight. They were frozen in aliquot at À701C until they were used in EMSA experiments. Initially, purified recombinant proteins were used in EMSA. Later experiments showed that the same results were observed when fusion proteins were used. Subsequently, fusion proteins were used in all EMSA. The recombinant proteins used in this study are listed in Table 2 .
Preparation of nuclear extracts and EMSA
Nuclear extracts from various cell lines were prepared following the procedure described (John et al., 1983) . The extracts were dialysed in 20 mm HEPES pH 7.9, 20% glycerol, 0.1 m KCl, 0.2 mm EDTA, 0.5 mm PMSF, and 0.5 mm DTT. PMSF and DTT were added fresh before use. The extracts were aliquoted and snap-frozen in liquid nitrogen and stored at À701C.
To prepare oligonucleotides for the EMSA, 500 ng each of sense and antisense oligonucleotides were mixed in 100 ml water, heated at 601C for 15 min, then slowly cooled down to 41C. Double-stranded oligonucleotides (100 ng) were end labeled with 32 P (specific activity, 1À5 Â 10 7 /mg). For the EMSA reaction, 1 ng of labeled probe (10 000-50 000 c.p.m./ sample) was mixed with equal amounts of nuclear extracts (3 mg/ml) or bacterially synthesized recombinant proteins (3 mg/ ml) in 40 ml buffer containing 10 mm HEPES pH 7.9, 10 mm KCl, 5 mm MgCl 2 , 1 mm DTT, 1 mg poly(dI-dC), and 10% glycerol. The mixtures were kept on ice for 1 h, then loaded onto a 6% polyacrylamide gel and electrophoresed at 150 V in 1 Â TBE buffer (22.5 mm Tris-borate, 0.5 mm EDTA pH 8.0).
For supershift EMSA, the 32 P-labeled probe (10 000-50 000 c.p.m./sample) was incubated with 3 mg of nuclear extract from A2058 cells on ice for 30 min. Antibodies against AML-1a N-20 (3 or 5 mg/sample), C/EBPa N-19 (3 or 5 mg/ sample), and C/EBPa C-18 (3 or 5 mg/sample) (Santa Cruz) were added and incubated at room temperature for 30 min. The reactions were separated by electrophoresis on a 6% polyacrylamide gel at 150 V in 1 Â TBE buffer (22.5 mm Trisborate, 0.5 mm EDTA pH 8.0).
Transfection and luciferase assay
At 12-24 h before transfection, A2058 cells were plated at 1-2 Â 10 5 cells per well in a six-well cell culture plate. A 2 mg measure of various DNA constructs and 0.3 mg of Renilla construct (Promega) were mixed with 10 ml of Superfect (Qiagen). The mixture was incubated at room temperature for 10 min. After washing the cells with 1 Â PBS, the DNA/ Superfect mixtures were transferred to the cells and incubated at 371C in a CO 2 incubator for 24 h. When cotransfection with constructs expressed various transcription factors, appropriate control plasmids such as pcDNA3 and pGL3 were also transfected into separate cultured cells as controls, and DNA was maintained in equal amounts. Subsequently, the transfected cells were washed with 1 Â PBS and cultured for an additional 48 h in DMEM with 10% FCS. At the end of 48 h incubation, the transfected cells were lysed with reporter lysis buffer (Promega). The enzymatic activity was measured for firefly and Renilla luciferase using Dual-Luciferase Reporter assay System (Promega) and a luminometer. All luciferase assays were carried out in duplicates or triplicates and experiments were carried out at least twice.
